Peter Redfield has been invited to be a member of the Data and Safety Monitoring Board (DSMB) for the therapeutic clinical trial: “Efficacy of favipiravir in reducing mortality in adults at early stage of Eboal virus Disease in Guinea: a phase IIb Trial”, for which the French health agency Inserm is the sponsor.
Also, the media continue to consult with Peter in relation to MSF (Doctors Without Borders) and Ebola:
Ebola: Doctors Without Borders Shows How to Manage a Plague